Zelboraf Interactions
There are 623 drugs known to interact with Zelboraf (vemurafenib), along with 7 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 228 are major, 374 are moderate, and 21 are minor.
- View all 623 medications that may interact with Zelboraf
- View Zelboraf alcohol/food interactions (1)
- View Zelboraf disease interactions (7)
Most frequently checked interactions
View interaction reports for Zelboraf (vemurafenib) and the medicines listed below.
- Adcetris (brentuximab)
- Aspirin Low Strength (aspirin)
- atorvastatin
- Biaxin (clarithromycin)
- bleomycin
- Blincyto (blinatumomab)
- Bosulif (bosutinib)
- Caprelsa (vandetanib)
- Cosentyx (secukinumab)
- Cotellic (cobimetinib)
- Cymbalta (duloxetine)
- Eltroxin (levothyroxine)
- Erivedge (vismodegib)
- Esbriet (pirfenidone)
- Hizentra (immune globulin subcutaneous)
- Imbruvica (ibrutinib)
- Kalydeco (ivacaftor)
- Kynamro (mipomersen)
- Luxturna (voretigene neparvovec ophthalmic)
- Lyrica (pregabalin)
- Mekinist (trametinib)
- metformin
- Nexium (esomeprazole)
- Nydrazid (isoniazid)
- Ofev (nintedanib)
- Oncovin (vincristine)
- Sabril (vigabatrin)
- Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil)
- Tafinlar (dabrafenib)
- tamsulosin
Zelboraf alcohol/food interactions
There is 1 alcohol/food interaction with Zelboraf (vemurafenib).
Zelboraf disease interactions
There are 7 disease interactions with Zelboraf (vemurafenib) which include:
- lung toxicity
- cutaneous malignancies
- dermatological reactions
- hepatic impairment
- QT prolongation
- renal impairment
- visual complications
Report options
More about Zelboraf (vemurafenib)
- Zelboraf consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Dacarbazine
Dacarbazine systemic is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Ipilimumab
ipilimumab (Yervoy) is an immunotherapy used for melanoma, renal cell carcinoma, non-small cell ...
Dabrafenib
Dabrafenib systemic is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer ...
Trametinib
Trametinib systemic is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
